Golden Biotechnology Corporation
Golden Biotechnology Corporation engages in research and development of new drug in Taiwan. The company offers Antroquinonol for the treatment of pancreatic cancer, acute myeloid leukemia, blood diseases, non-small cell lung cancer, COVID-19, and other diseases. It is also involved in development and sale of health foods and supplements, as well as provides products for oncology, infectious, and … Read more
Market Cap & Net Worth: Golden Biotechnology Corporation (4132)
Golden Biotechnology Corporation (TWO:4132) has a market capitalization of $70.77 Million (NT$2.34 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #20848 globally and #1111 in its home market, demonstrating a -9.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Golden Biotechnology Corporation's stock price NT$12.85 by its total outstanding shares 182227000 (182.23 Million).
Golden Biotechnology Corporation Market Cap History: 2015 to 2026
Golden Biotechnology Corporation's market capitalization history from 2015 to 2026. Data shows change from $467.00 Million to $70.77 Million (-8.11% CAGR).
Golden Biotechnology Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Golden Biotechnology Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.44x
Golden Biotechnology Corporation's market cap is 3.44 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $180.28 Million | $83.29 Million | -$285.12 Million | 2.16x | N/A |
| 2020 | $262.86 Million | $88.83 Million | -$391.38 Million | 2.96x | N/A |
| 2021 | $710.49 Million | $81.77 Million | -$443.84 Million | 8.69x | N/A |
| 2022 | $330.46 Million | $217.82 Million | -$271.88 Million | 1.52x | N/A |
| 2023 | $218.38 Million | $63.43 Million | -$361.64 Million | 3.44x | N/A |
Competitor Companies of 4132 by Market Capitalization
Companies near Golden Biotechnology Corporation in the global market cap rankings as of March 19, 2026.
Key companies related to Golden Biotechnology Corporation by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Golden Biotechnology Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Golden Biotechnology Corporation's market cap moved from $467.00 Million to $ 70.77 Million, with a yearly change of -8.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$70.77 Million | -46.46% |
| 2025 | NT$132.18 Million | +54.34% |
| 2024 | NT$85.64 Million | -60.78% |
| 2023 | NT$218.38 Million | -33.92% |
| 2022 | NT$330.46 Million | -53.49% |
| 2021 | NT$710.49 Million | +170.29% |
| 2020 | NT$262.86 Million | +45.80% |
| 2019 | NT$180.28 Million | +17.89% |
| 2018 | NT$152.92 Million | -29.90% |
| 2017 | NT$218.15 Million | -15.91% |
| 2016 | NT$259.41 Million | -44.45% |
| 2015 | NT$467.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Golden Biotechnology Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $70.77 Million USD |
| MoneyControl | $70.77 Million USD |
| MarketWatch | $70.77 Million USD |
| marketcap.company | $70.77 Million USD |
| Reuters | $70.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.